Biocartis launches its flagship diagnostics platform Idylla

12.09.2014 08:59

With the launch of Idylla, Biocartis aims to set a new golden standard in molecular diagnostics. Idylla’s first test identifies cancers driven by the BRAF oncogene. Cancer patients will benefit significantly from faster therapy decisions and better guidance of treatment choices.

Biocartis, an innovative molecular diagnostics company, announced today that it has officially launched its flagship molecular diagnostics system Idylla. Idylla’s ease of use, access on-demand design, speed and superior sensitivity are unprecedented in the field of molecular diagnostics. Together with Idylla, Biocartis also released its first oncology assay, the Idylla BRAF Mutation Test.

“Molecular testing plays a key role in the treatment decision process. It allows doctors to select specifically designed therapies based on the genetic profile of their patient”, said Rudi Pauwels, CEO & Executive Chairman of Biocartis. “Traditionally, molecular diagnostics involves a series of specialized, labor-intensive and time-consuming steps. As a result, most labs do not perform these tests in-house, but send them to specialized labs where they are batched, often delaying treatment decisions.”

Idylla, Biocartis’ fully automated, real-time PCR system, sets the standard for a novel way of molecular testing. Idylla’s access on-demand design allows clinicians to initiate a new test at any given time, without the need for batching or for trained operators. The system’s short turnaround time – between 35 and 120 minutes – enables laboratories to report same-day results, significantly speeding up the treatment decision process. Furthermore, Idylla’s multiplex capability offers the possibility to detect up to 30 molecular targets simultaneously in the same sample, making the system very well suited for more complex assays.

The BRAF Mutation Test is Idylla’s first oncology test and is designed to determine the most appropriate treatment for a specific type of skin cancer. The assay can detect mutations directly from tissue slices in about 90 minutes. The excellent analytical sensitivity of the Idylla BRAF Mutation Test was demonstrated during clinical performance studies. Rudi Pauwels added: “Biocartis has the crucial expertise in house to bring a whole new generation of diagnostic tests for oncology and infectious diseases to the market. Furthermore, we are also working with Janssen Pharmaceutica and Abbott Molecular to develop a range of diagnostic tests in other disease areas.”

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines


Apply for EC Award 2017

Application for the awards of the ETH Entrepreneurship Club is open until 27 October. Do not miss the deadline.